Shopping Cart 0
Cart Subtotal
USD 0

Akcea Therapeutics Inc (AKCA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Akcea Therapeutics Inc (Akcea Therapeutics), a subsidiary of Ionis Pharmaceuticals Inc, is a developer and commercializer of drugs to treat patients with cardiometabolic diseases caused by lipid disorders. The company's drugs are designed based on advanced antisense technology. Its pipeline product includes volanesorsen, an antisense drug that reduces ApoC-III protein production and lowers triglycerides in patients with dyslipidemia. Akcea Therapeutics also offer products for recurring cardiovascular disease with high lipoprotein, calcific aortic stenosis with high lipoprotein, severe high triglycerides, mixed dyslipidemias and high triglycerides with type 2 diabetes, among others. It also conducts clinical trials for the development of its products. Akcea Therapeutics is headquartered in Cambridge, Massachusetts, the US.

Akcea Therapeutics Inc (AKCA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Akcea Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Novartis Enters into Option Agreement with Ionis Pharma and Akcea Therapeutics 11

Licensing Agreements 13

PTC Therapeutics Enters into Licesing Agreement with Akcea Therapeutics 13

Akcea Therapeutics Enters into Licensing Agreement with Ionis Pharma 14

Akcea Therapeutics Inc-Key Employees 17

Akcea Therapeutics Inc-Locations And Subsidiaries 18

Head Office 18

Recent Developments 19

Strategy And Business Planning 19

Sep 06, 2017: Akcea Therapeutics Establishes Canadian Subsidiary 19

Financial Announcements 20

Aug 06, 2018: Akcea reports financial results and highlights for second quarter 2018 20

May 03, 2018: Akcea Reports Financial Results and Highlights for First Quarter 2018 22

Feb 26, 2018: Akcea Reports Financial Results and Highlights for Fourth Quarter and Year End 2017 24

Nov 06, 2017: Akcea Reports Financial Results and Highlights for Third Quarter 2017 26

Aug 08, 2017: Akcea Reports Financial Results and Highlights for Second Quarter 2017 28

Corporate Communications 30

Oct 08, 2018: Akcea announces changes to Board of Directors 30

Jun 05, 2018: Akcea Therapeutics Names Dr. Richard Moscicki As Board Director 31

Apr 17, 2018: Sarah Boyce Joins Akcea Therapeutics As President And Member Of Board Of Directors 32

Sep 05, 2017: Akcea Expands Leadership Team in Preparation for First Commercial Launch 33

May 09, 2017: Akcea Therapeutics Announces Appointment of Edward Fitzgerald to Board of Directors 35

Mar 28, 2017: Akcea Therapeutics Announces Three Additions to Board of Directors 36

Product News 37

10/16/2017: Akcea Presents Data Demonstrating Significant Burden of Illness in Familial Chylomicronemia Syndrome 37

07/11/2017: New Data Reveal Hidden Burden of Familial Chylomicronaemia Syndrome 38

05/02/2018: Akcea Announces Expansion of Global Early Access Program to Provide Volanesorsen to People Living with FCS 39

03/21/2018: MHRA Grants UK Patients Early Access to Akcea Therapeutics' Volanesorsen for Familial Chylomicronaemia Syndrome (FCS) 40

03/12/2018: Positive Phase 1/2 Results of AKCEA-APOCIII-LRx Presented at American College of Cardiology Annual Scientific Session & Expo 41

02/28/2018: Akcea Therapeutics Recognizes Rare Disease Day by Spotlighting Several Historic "Firsts" for People Living with Familial Chylomicronemia Syndrome 43

02/15/2018: Akcea Announces FDA Advisory Committee Meeting to Review Volanesorsen as a Treatment for Familial Chylomicronemia Syndrome 44

Product Approvals 45

Nov 15, 2017: Akcea and Ionis Announce Acceptance of Marketing Applications in U.S., EU and Canada for Volanesorsen for the Treatment of FCS 45

Oct 10, 2017: Akcea Therapeutics' Volanesorsen Receives Promising Innovative Medicine (PIM) Status for the Treatment of Familial Chylomicronaemia Syndrome (FCS) 46

Sep 12, 2017: Akcea Announces Filing of New Drug Submission for Volanesorsen to Health Canada 47

Aug 31, 2017: Akcea and Ionis Announce Submission of New Drug Application for Volanesorsen to the U.S. FDA 49

Jul 27, 2017: Akcea and Ionis Announce Submission of Marketing Authorization Application for Volanesorsen to the European Medicines Agency 51

Clinical Trials 52

Apr 26, 2018: Akcea Therapeutics Announces Presentations on Volanesorsen and FCS at the National Lipid Association Scientific Sessions 52

Jan 05, 2018: Akcea Initiates Phase 2b Study of AKCEA-APOCIII-LRx in Patients with Hypertriglyceridemia and Established Cardiovascular Disease 53

Oct 31, 2017: Akcea and Ionis Report Positive Phase 1/2a Data with AKCEA-APOCIII-LRx 55

Aug 08, 2017: Akcea Provides Update on AKCEA-APOCIII-LRx 56

Mar 30, 2017: Akcea Initiates Phase 2 Study of AKCEA-APO(a)-L Rx in Patients with High Lp(a) and Cardiovascular Disease 57

Mar 06, 2017: Akcea and Ionis Announce Positive Results from Pivotal Study of Volanesorsen in Patients with Familial Chylomicronemia Syndrome 58

Other Significant Developments 60

Jun 12, 2018: Akcea and Ambry Genetics to Launch hATTR Compass, a Genetic Testing Program for People with Suspected Hereditary ATTR Amyloidosis 60

Appendix 61

Methodology 61

About GlobalData 61

Contact Us 61

Disclaimer 61


List Of Figure

List of Figures

Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Akcea Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Akcea Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Akcea Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Novartis Enters into Option Agreement with Ionis Pharma and Akcea Therapeutics 11

PTC Therapeutics Enters into Licesing Agreement with Akcea Therapeutics 13

Akcea Therapeutics Enters into Licensing Agreement with Ionis Pharma 14

Akcea Therapeutics Inc, Key Competitors 16

Akcea Therapeutics Inc, Key Employees 17

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Akcea Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.